The ABCs of antiphospholipid syndrome

DİNÇER A. B. K., ERKAN D.

Archives of Rheumatology, vol.38, no.2, pp.163-173, 2023 (SCI-Expanded, Scopus, TRDizin) identifier identifier identifier

  • Publication Type: Article / Review
  • Volume: 38 Issue: 2
  • Publication Date: 2023
  • Doi Number: 10.46497/archrheumatol.2023.41875
  • Journal Name: Archives of Rheumatology
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, CINAHL, EMBASE, TR DİZİN (ULAKBİM)
  • Page Numbers: pp.163-173
  • Ankara Yıldırım Beyazıt University Affiliated: No

Abstract

Antiphospholipid syndrome (APS) is a thromboinflammatory syndrome characterized by thrombotic, microvascular, obstetric, or non-thrombotic events in the setting of persistent antiphospholipid antibodies (aPL), namely anticardiolipin antibody (aCL), anti-β2 glycoprotein-I antibody (aβ2GPI), and lupus anticoagulant (LA). The diagnosis of APS requires careful assessment of the aPL profile, the clinical phenotype, and additional risk factors. The standard management of aPL-related thrombosis is anticoagulation, which is not effective for microvascular and non-thrombotic events. In parallel to our improved understanding of aPL-related mechanisms, the role of immunosuppression has been increasingly investigated. In this review, we summarize the basic concepts and future perspectives in APS.